Lone Pine Capital's 13F portfolio value increased slightly from $13.41B to $13.47B. Check out the new stakes and significant ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS ...

With the market underpricing its earnings stability and future catalysts, Pfizer presents a compelling defensive investment ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the ...

TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...

Merck last year signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to ...

If you believed everything you read on social media, you’d think HHS Secretary Robert F. Kennedy Jr. had issued a sweeping ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

Unlike the US, Europe or other developed markets, Mounjaro will have to be purchased out-of-pocket in India, as obesity is ...

Organovo (ONVO) announced the close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (LLY). The ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.